RxDoctor Payments Data

Avani Shah, MD

Ophthalmology · Allentown, PANPI 1255328373

Payments from drug & device makers

$910in general payments, 2019–2025

Across 27 payments — averaging $33.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$361
  • Medtronic$97
  • AbbVie$74
  • Novartis$67
  • Amgen$67
  • Omeros Corporation$51
  • plus $194 from 7 others

What the payments were for

  • Food & beverage$89198%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$910 in reported general payments places this provider in the 40th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$151,386
Medicare patients
441
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine161$183,417
Cyclosporine134$74,436
Prednisolone Acetate273$17,437
LumiganBimatoprost20$16,803
XiidraLifitegrast12$10,698
RocklatanNetarsudil Mesylat/Latanoprost13$6,000
Ketorolac Tromethamine179$5,591
Brimonidine Tartrate120$3,960
Ofloxacin153$3,651
Latanoprost228$3,557
Gatifloxacin24$2,023
Travoprost20$1,468
ErythromycinErythromycin Base53$1,375
Timolol Maleate74$1,069
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat44$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$74$200,220181 claims
Aerie Pharmaceuticals, Inc.Rocklatan$24$6,00013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →